Munich Startup
RNATICS GmbH

RNATICS GmbH

RNATICS develops medicines based on short nucleic acid molecules, so-called oligonucleotides, that target disease-causing RNAs in tissue-resident macrophages. This novel delivery mechanism enables access to organs that have previo...

Founded2021
Business ModelB2B
IndustryBioTech
This content was machine translated.

About RNATICS GmbH

RNATICS develops medicines based on short nucleic acid molecules, so-called oligonucleotides, that target disease-causing RNAs in tissue-resident macrophages. This novel delivery mechanism enables access to organs that have previously been inaccessible for nucleic acid therapies, opening up significant therapeutic potential in many diseases. We plan to start the first clinical trial (Phase I) of our lead candidate, RCS-21, for the treatment of fibrotic lung disease following viral infections (e.g. COVID-19) in spring 2024.

More like this

Discover more articles, startups, and events from the ecosystem

European Founder Report: Europe’s Startup Boom Has a Funding Problem
Ecosystem

European Founder Report: Europe’s Startup Boom Has a Funding Problem

25.09.26
4 Min.
17 Munich Institutions Found Women Entrepreneurs Alliance
Ecosystem

17 Munich Institutions Found Women Entrepreneurs Alliance

25.09.26
3 Min.
AI Security Startup Kontext Raises €3.5 Million for Secure AI Agents
Deals

AI Security Startup Kontext Raises €3.5 Million for Secure AI Agents

24.09.26
4 Min.